Last updated: August 11, 2025
Introduction
The World Intellectual Property Organization (WIPO) patent application WO2015095793 pertains to innovative drug formulations and manufacturing methods designed to enhance therapeutic efficacy while optimizing stability and bioavailability. As global intellectual property landscapes evolve rapidly, understanding the scope of this patent, its claims, and its positioning within the broader patent ecosystem is essential for pharmaceutical entities, investors, and legal professionals engaged in strategic patent licensing, research, and development.
Patent Overview
WO2015095793 is a Patent Cooperation Treaty (PCT) application published in June 2015, indicating an applicant’s intent to secure patent protection across multiple jurisdictions. The application describes novel compositions and methods for producing pharmaceutical compounds, emphasizing improved pharmacokinetics, stability, and patient compliance.
Technical Field
The invention primarily resides within the pharmaceutical chemistry domain, with focus areas including:
- Oral drug formulations
- Controlled-release systems
- Improved bioavailability of active pharmaceutical ingredients (APIs)
- Stabilization of bioactive compounds during manufacturing and storage
Scope of the Patent: Core Innovations
1. Formulation Content and Composition
The patent describes a drug formulation that includes:
- An active pharmaceutical ingredient (API), specifically a class of compounds with known therapeutic activity.
- Pharmacologically acceptable excipients, carriers, and stabilizers.
- Specific ratios and concentration ranges that optimize dissolution, absorption, and stability.
The key innovation lies in a specific combination of excipients that enhances the chemical stability of sensitive APIs under various storage conditions while maintaining bioavailability.
2. Manufacturing Process
A novel manufacturing procedure is claimed, involving:
- A multi-step process of blending, granulation, and coating.
- The use of specific solvents and drying conditions to preserve API integrity.
- Techniques for controlling particle size and morphology, contributing to uniformity and predictable drug release profiles.
3. Controlled Release and Bioavailability Enhancement
A significant aspect of the invention is a controlled-release mechanism that prolongs drug plasma levels, reducing dosing frequency and improving patient compliance. This is achieved by:
- Developing matrix systems or coating techniques that modulate dissolution rates.
- Incorporating excipients that slow degradation or release rates.
Claims Analysis
The claims define the legal scope of the invention. The key claims in WO2015095793 can be categorized as follows:
1. Composition Claims
- Primary claim: A pharmaceutical composition comprising a specific API in combination with particular excipients achieving enhanced stability and bioavailability.
- Dependent claims: Enumerate ranges for excipient concentrations, specific API derivatives, and optional inclusion of stabilizers or solubilizers.
2. Process Claims
- Methods of manufacturing the composition involve specific steps of mixing, granulation, coating, and drying.
- Claims specify temperature ranges, solvents, and process parameters that are critical to achieving the desired formulation attributes.
3. Use and Method Claims
- Claims extend to methods of treatment using the composition.
- Specific indications include chronic conditions requiring consistent plasma drug levels.
4. Device and Delivery System Claims
- Though less prominent, some claims may encompass delivery devices or system integrations that facilitate controlled release.
Patent Landscape and Competitive Positioning
Global Patent Filing Strategy
- The WO2015095793 application indicates an intent to secure broad international coverage, with national phase entries likely in the US, Europe, China, India, and other key markets.
- The applicant may have prioritized jurisdictions with significant pharmaceutical markets or where similar technologies face competitive challenges.
Prior Art and Patentability
- WO2015095793 builds upon existing knowledge, including prior formulations and controlled-release systems (e.g., US patents on matrix systems).
- Patentability hinges on demonstrating inventive step over prior art, particularly the specific combination of excipients and manufacturing conditions.
Patent Family and Related Filings
Freedom-to-Operate and Infringement Risks
- A comprehensive landscape suggests that key competitors have filed patents on specific excipient mixtures and production processes, necessitating careful freedom-to-operate analyses.
- The scope of claims in WO2015095793, though broad, may face challenges if prior art discloses similar compositions or processes.
Regulatory and Commercial Implications
- Formulations described may qualify for regulatory approvals under pharmaceutical guidelines, provided stability and efficacy data support claims.
- The controlled-release aspect aligns with market trends favoring long-acting formulations, expanding market potential.
Legal and Strategic Considerations
- The specificity of claims can impact enforceability; overly broad claims risk invalidation, while narrow claims limit scope.
- Patent enforcement environments vary; patent holders should monitor potential infringement and licensing opportunities.
- Licensing negotiations can leverage the patent's claims to improve proprietary positioning or secure co-development deals.
Key Takeaways
- Broad Composition and Process Coverage: WO2015095793 encompasses innovative drug formulations with tailored excipient combinations and nuanced manufacturing processes, aiming to improve pharmacokinetics and stability.
- Strong Strategic Positioning: The patent’s international filing approach indicates a focus on securing global market rights, which is critical for expanding proprietary assets.
- Competitive Landscape: Similar filings by competitors necessitate ongoing vigilance regarding patent overlapping and potential freedom-to-operate issues.
- Regulatory Fit: The formulation innovations could meet regulatory standards efficiently, given supporting stability and bioavailability data.
- Intellectual Property Optimization: Entities seeking to develop similar technologies must consider designing around similar compositions or processes to avoid infringement, or leverage licensing opportunities.
FAQs
Q1. What are the key inventive features of WO2015095793?
The key innovations include specific combinations of excipients that enhance drug stability and bioavailability, coupled with manufacturing methods that preserve API integrity and enable controlled-release profiles.
Q2. How broad are the claims of this patent, and what are their limitations?
Claims encompass pharmaceutical compositions with specified excipient ratios, manufacturing processes, and therapeutic methods. Limitations arise based on the specificity of excipient types, concentrations, and process parameters.
Q3. Which markets are most relevant for patent protection of this invention?
Prioritization of US, Europe, China, and India is typical, as they represent major pharmaceutical markets with diverse patent enforcement environments.
Q4. How does this patent landscape compare to existing controlled-release drug patents?
While it shares common themes—such as controlled-release mechanisms—the detailed combination of excipients and manufacturing steps may provide a novel patentable niche, differentiating it from existing patents.
Q5. What strategies should companies consider if developing similar formulations?
Companies should analyze the claims for potential infringement, explore alternative formulations or manufacturing methods, or consider licensing opportunities based on the patent's scope.
References
- WIPO Patent Application WO2015095793.
- Prior art patents on controlled-release formulations and stabilizing excipients.
- Patent landscape reports on controlled-release drug formulations.
- Regulatory guidelines for pharmaceutical stability and bioavailability.
Note: The above analysis is based on publicly available patent documentation and standard pharmaceutical patent practices. For specific legal advice or detailed infringement analysis, professional patent counsel should be consulted.
